Literature DB >> 8659579

Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study.

D P Han1, S R Wisniewski, L A Wilson, M Barza, A K Vine, B H Doft, S F Kelsey.   

Abstract

PURPOSE: To determine the microbiologic spectrum and antibiotic susceptibilities of infecting organisms in postoperative endophthalmitis and to evaluate the effects of operative factors on the microbiologic spectrum.
METHODS: Patients with bacterial endophthalmitis presenting within six weeks of cataract extraction or secondary intraocular lens implantation (IOL) were evaluated. Cultures and Gram stains were performed on intraocular specimens and susceptibility tests on the isolates.
RESULTS: Confirmed microbiologic growth was demonstrated from intraocular specimens from 291 of 420 patients (69.3%). Gram-positive bacteria were isolated from 274 patients (94.2%) with confirmed growth and gram-negative bacteria from 19 (6.5%). Two hundred twenty-six of the 323 isolates obtained (70.0%) were gram-positive, coagulase-negative micrococci, 32 (9.9%) Staphylococcus aureus, 29 (9.0%) Streptococcus species, seven (2.2%) Enterococcus species, ten (3.1%) miscellaneous gram-positive species, and 19 (5.9%) gram-negative species. All gram-positive isolates tested were susceptible to vancomycin. Seventeen gram-negative isolates (89%) were susceptible to both amikacin and ceftazidime and two (11%) were resistant to both. Anterior chamber or secondary IOL implantations were associated with higher rates of infection with gram-positives other than coagulase-negative micrococci than were posterior chamber IOL implantations (P = .022) or primary cataract extractions (P = .024).
CONCLUSIONS: Gram-positive, coagulase-negative micrococci predominated in this series. Vancomycin was active against all gram-positive isolates tested. Amikacin and ceftazidime showed equivalent activity against gram-negative isolates. Secondary or anterior chamber lens implantations were associated with a possible spectrum shift toward gram-positive organisms other than the coagulase-negative micrococci.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8659579     DOI: 10.1016/s0002-9394(14)71959-2

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  137 in total

1.  Macular infarction after intravitreal amikacin: mounting evidence against amikacin.

Authors:  G Galloway; A Ramsay; K Jordan; A Vivian
Journal:  Br J Ophthalmol       Date:  2002-03       Impact factor: 4.638

Review 2.  The microbiology of endophthalmitis: global trends and a local perspective.

Authors:  Y Keynan; Y Finkelman; P Lagacé-Wiens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-05       Impact factor: 3.267

3.  Post-traumatic endophthalmitis in 143 eyes of children and adolescents from India.

Authors:  E Rishi; P Rishi; V V Koundanya; C Sahu; R Roy; P S Bhende
Journal:  Eye (Lond)       Date:  2016-02-12       Impact factor: 3.775

4.  Diagnostic performance of blood culture bottles for vitreous culture compared to conventional microbiological cultures in patients with suspected endophthalmitis.

Authors:  Jan Kehrmann; Valerie Chapot; Jan Buer; Philipp Rating; Norbert Bornfeld; Joerg Steinmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-01-09       Impact factor: 3.267

5.  Immunization with pneumolysin protects against both retinal and global damage caused by Streptococcus pneumoniae endophthalmitis.

Authors:  Melissa E Sanders; Erin W Norcross; Quincy C Moore; Jonathan Fratkin; Hilary Thompson; Mary E Marquart
Journal:  J Ocul Pharmacol Ther       Date:  2010-10-29       Impact factor: 2.671

6.  [Rational antibiotic therapy in ophthalmology].

Authors:  W Behrens-Baumann; U Frank; T Ness
Journal:  Ophthalmologe       Date:  2010-04       Impact factor: 1.059

7.  Intravitreal human immune globulin in a rabbit model of Staphylococcus aureus toxin-mediated endophthalmitis: a potential adjunct in the treatment of endophthalmitis.

Authors:  Dennis P Han
Journal:  Trans Am Ophthalmol Soc       Date:  2004

8.  Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration.

Authors:  Seenu M Hariprasad; William E Mieler; Gaurav K Shah; Kevin J Blinder; Rajendra S Apte; Nancy M Holekamp; Matthew A Thomas; Jingduan Chi; Randall A Prince
Journal:  Trans Am Ophthalmol Soc       Date:  2004

9.  Reduction of preoperative conjunctival bacterial flora with the use of mupirocin nasal ointment.

Authors:  Terry J Alexandrou; Seenu M Hariprasad; Joseph Benevento; Michael P Rubin; Michael Saidel; Susan Ksiazek; Kenneth Thompson; Sue Boonlayangoor; William F Mieler
Journal:  Trans Am Ophthalmol Soc       Date:  2006

10.  Clinical outcomes and antibiotic susceptibilities of Staphylococcus aureus endophthalmitis.

Authors:  Jonathan I Huz; Krishna Mukkamala; Ivelisse Rodriguez Pagan; David Ritterband; Mahendra Shah; Ronald C Gentile; Michael Engelbert
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-10-19       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.